These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 3755402)

  • 1. Stereoselective inhibition of prolactin secretion by (-)-HW-165, a novel 3-PPP congener; further support for similarities between central DA autoreceptors and pituitary lactotroph DA receptors.
    Hjorth S; Eriksson E; Andersson B
    Eur J Pharmacol; 1986 Jun; 125(3):421-8. PubMed ID: 3755402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central dopaminergic properties of HW-165 and its enantiomers; trans-octahydrobenzo(f)quinoline congeners of 3-PPP.
    Hjorth S; Svensson K; Carlsson A; Wikström H; Andersson B
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Jul; 333(3):205-18. PubMed ID: 3762735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (+)- and (-)-3-PPP exhibit different intrinsic activity at striatal dopamine autoreceptors controlling dopamine synthesis.
    Clark D; Hjorth S; Carlsson A
    Eur J Pharmacol; 1984 Oct; 106(1):185-9. PubMed ID: 6099268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The intrinsic activity of (-)-3-PPP (preclamol) on pituitary DA receptors in female rats is enhanced following chronic DA depletion.
    Carlsson M; Eriksson E
    Life Sci; 1988; 42(5):585-8. PubMed ID: 3339950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The intrinsic activities of the partial dopamine receptor agonists (-)-3-PPP and TDHL on pituitary dopamine receptors are lower in female than in male rats.
    Carlsson M; Carlsson A; Eriksson E
    Eur J Pharmacol; 1987 Oct; 142(1):39-43. PubMed ID: 3691635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of (+)- and (-)-3-PPP with the dopamine receptor in the anterior pituitary gland.
    Mikuni M; Gudelsky GA; Simonovic M; Meltzer HY
    Life Sci; 1984 Jan; 34(3):239-46. PubMed ID: 6694521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sexually differentiated actions of 3-PPP enantiomers on prolactin secretion.
    Carlsson M; Eriksson E; Nilsson C; Carlsson A
    Neuropharmacology; 1986 Aug; 25(8):951-4. PubMed ID: 3774120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopaminergic stimulation of prolactin release.
    Denef C; Manet D; Dewals R
    Nature; 1980 May; 285(5762):243-6. PubMed ID: 6154895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of functional evidence for the involvement of sigma opiate receptors in the actions of the 3-PPP enantiomers on central dopaminergic systems: discrepancies between in vitro and in vivo observations.
    Hjorth S; Clark D; Carlsson A
    Life Sci; 1985 Aug; 37(7):673-84. PubMed ID: 2410756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine receptors involved in prolactin secretion pharmacologically characterized by means of 3-PPP enantiomers.
    Eriksson E; Modigh K; Carlsson A; Wikström H
    Eur J Pharmacol; 1983 Dec; 96(1-2):29-36. PubMed ID: 6662196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the two partial D2 agonists (+)- and (-)-3-PPP on prolactin release in EEDQ treated male rats.
    Ekman A; Quiding M; Eriksson E
    Life Sci; 1991; 48(4):311-20. PubMed ID: 1671291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence.
    Clark D; Hjorth S; Carlsson A
    J Neural Transm; 1985; 62(1-2):1-52. PubMed ID: 3894582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP.
    Hjorth S; Carlsson A; Clark D; Svensson K; Wikström H; Sanchez D; Lindberg P; Hacksell U; Arvidsson LE; Johansson A
    Psychopharmacology (Berl); 1983; 81(2):89-99. PubMed ID: 6415751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postsynaptic dopamine agonistic effects of 3-PPP enantiomers revealed by bilateral 6-hydroxy-dopamine lesions and by chronic reserpine treatment in rats.
    Arnt J; Hyttel J
    J Neural Transm; 1984; 60(3-4):205-23. PubMed ID: 6441835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine (DA) autoreceptor efficacy of 3-PPP enantiomers after short-term synaptic DA deprivation.
    Hjorth S; Clark D; Carlsson A
    Eur J Pharmacol; 1988 Aug; 152(3):207-15. PubMed ID: 3146512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agonist and antagonist effects of 3-PPP enantiomers on functional dopamine autoreceptors and postsynaptic dopamine receptors in vitro.
    Mulder AH; Draper R; Sminia P; Schoffelmeer AN; Stoof JC
    Eur J Pharmacol; 1985 Jan; 107(3):291-7. PubMed ID: 3979429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of the enantiomers of 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP) at dopamine receptor sites.
    Koch SW; Koe BK; Bacopoulos NG
    Eur J Pharmacol; 1983 Sep; 92(3-4):279-83. PubMed ID: 6138267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-substituted 1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines and 3-phenylpiperidines: effects on central dopamine and sigma receptors.
    Wikström H; Andersson B; Elebring T; Svensson K; Carlsson A; Largent B
    J Med Chem; 1987 Dec; 30(12):2169-74. PubMed ID: 2824773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological profiles of the putative dopamine autoreceptor agonists 3-PPP and TL-99.
    Martin GE; Haubrich DR; Williams M
    Eur J Pharmacol; 1981 Nov; 76(1):15-23. PubMed ID: 7318920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the mode of action of 3-(3-hydroxyphenyl)-N-n-propylpiperidine, 3-PPP, and its enantiomers. With particular reference to dopaminergic mechanisms in the central nervous system.
    Hjorth S
    Acta Physiol Scand Suppl; 1983; 517():1-52. PubMed ID: 6138921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.